anti-HER2 CAR T-cell therapy (Baylor College of Medicine)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-HER2 CAR T-cell therapy (Baylor College of Medicine)

Drug Alias NameHER2/CMV bispecific T cells

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulators

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsSolid tumoursGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBaylor College Of Medicine

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBaylor College Of Medicine

Active IndicationsN/A

Inactive IndicationsSolid tumoursGlioblastoma

Other Information

ATC CodeN/A